To access this material please log in or register

Register Authorize

Cardiovascular coupling in heart failure patients with preserved left ventricular ejection fraction

Ovchinnikov A.G., Vitsenya M.V., Kulev B.D., Ageev F.T.
Federal State Budgetary Institution, “Russian Cardiology Research and Production Complex” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords: treatment, cardiovascular coupling, preserved ejection fraction, CHF

DOI: 10.18087 / rhfj.2014.3.1968

Many patients with HF and preserved LV EF (HF-PEF) have increased LV and arterial rigidity. This review discusses pathophysiological features of disturbed cardiovascular coupling and how this disturbance affects the heart function and reserve capabilities. Therapies focused on correction of the disturbed cardiovascular coupling in HF-PEF are considered.
  1. Kass DA, Kelly RP. Ventriculo-arterial coupling: concepts, assumptions, and applications.Ann Biomed Eng. 1992;20 (1):41–62.
  2. Redfield MM, Jacobsen SJ, Borlaug BA et al. Age- and gender-related ventricular-vascular stiffening: a community based study. Circulation. 2005;112 (15):2254–2262.
  3. Sunagawa K, Maughan W, Burkhoff D et al. Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol. 1983;245 (5 Pt 1):H773–780.
  4. De Tombe PP, Jones S, Burkhoff D et al. Ventricular stroke work and efficiency both remain nearly optimal despite altered vascular loading. Am J Physiol. 1993 Jun;264 (6 Pt 2):H1817–24.
  5. Asanoi H, Sasayama S, Kameyama T. Ventriculoarterial coupling in normal and failing heart in humans. Circ Res. 1989;65 (2):483–493.
  6. Najjar SS, Schulman SP, Gerstenblith G et al. Age and gender affect ventricular-vascular coupling during aerobic exercise. J Am Coll Cardiol. 2004;44 (3):611–617.
  7. Avolio AP, Chen SG, Wang RP et al. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation. 1983 Jul;68 (1):50–8.
  8. Chen C. H, Nakayama M, Nevo E et al. Coupled systolic-ventricular and vascular stiffening with age implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol. 1998;32 (5):1221–1227.
  9. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction. Circulation. 2003;107 (5):714–720.
  10. Kelly RP, Ting CT, Yang TM et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 1992;86 (2):513–521.
  11. Segers P, Stergiopulos N, Westerhof N. Relation of effective arterial elastance to arterial system properties. Am J Physiol Heart Circ Physiol. 2002;282 (3):H1041–1046.
  12. Chemla D, Antony I, Lecarpentier Y, Nitenberg A. Contribution of systemic vascular resistance and total arterial compliance to effective arterial elastance in humans. Am J Physiol Heart Circ Physiol. 2003;285 (2):H614–620.
  13. Melenovsky V1, Borlaug BA, Rosen B et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling / dysfunction. J Am Coll Cardiol. 2007 Jan 16;49 (2):198–207.
  14. Lam CS, Roger VL, Rodeheffer RJ et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115 (15):1982–1990.
  15. Zile M, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350 (19):1953–1959.
  16. Borlaug BA, Kass DA. Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc Med. 2006 Nov;16 (8):273–9.
  17. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005 May;25 (5):932–43.
  18. Owan T. E, Redfield M. M. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47 (5):320–332.
  19. Klapholz M, Maurer M, Lowe AM et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol. 2004;43 (8):1432–1438.
  20. Borbély A, van der Velden J, Papp Z et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005 Feb 15;111 (6):774–81.
  21. van Heerebeek L, Borbely A, Niessen HW et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113 (16):1966–1973.
  22. Dauterman K, Pak PH, Maughan WL et al. Contribution of external forces to left ventricular diastolic pressure. Implications for the clinical use of the Starling law. Ann Intern Med. 1995 May 15;122 (10):737–42.
  23. Gandhi SK, Powers JC, Nomeir AM et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344 (1):17–22.
  24. Carroll JD, Carroll EP, Feldman T et al. Sex-associated diffe­rences in left ventricular function in aortic stenosis of the elderly. Circulation. 1992 Oct;86 (4):1099–107.
  25. Villari B, Campbell SE, Schneider J et al. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. Eur Heart J. 1995 Oct;16 (10):1410–9.
  26. Kass DA, Maughan WL. From 'Emax' to pressure-volume relations: a broader view. Circulation. 1988 Jun;77 (6):1203–12.
  27. Franciosa JA, Leddy CL, Wilen M, Schwartz DE. Relation between hemodynamic and ventilatory responses in determining exercise capacity in severe congestive heart failure. Am J Cardiol. 1984 Jan 1;53 (1):127–34.
  28. Gillebert TC, Leite-Moreira AF, De Hert SG. Load dependent diastolic dysfunction in heart failure. Heart Fail Rev. 2000 Dec;5 (4):345–55.
  29. Leite-Moreira AF, Correia-Pinto J, Gillebert TC. Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction. Cardiovasc Res. 1999 Aug 1;43 (2):344–53.
  30. Takimoto E, Soergel DG, Janssen PM et al. Frequency- and afterload-dependent cardiac modulation in vivo by troponin I with constitutively active protein kinase A phosphorylation sites. Circ Res. 2004 Mar 5;94 (4):496–504.
  31. Bilchick KC1, Duncan JG, Ravi R et al. Heart failure-associated alterations in troponin I phosphorylation impair ventricular relaxa­tion-afterload and force-frequency responses and systolic function. Am J Physiol Heart Circ Physiol. 2007 Jan;292 (1):H318–25.
  32. Brutsaert DL, Sys SU. Relaxation and diastole of the heart. Physiol Rev. 1989 Oct;69 (4):1228–315.
  33. Borlaug BA1, Melenovsky V, Redfield MM et al. Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol. 2007 Oct 16;50 (16):1570–7.
  34. Solomon SD, Janardhanan R, Verma A et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007 Jun 23;369 (9579):2079–87.
  35. Shapiro BP, Lam CS, Patel JB et al. Acute and chronic ventricular-arterial coupling in systole and diastole: insights from an elderly hypertensive model. Hypertension. 2007 Sep;50 (3):503–11.
  36. Saeki A, Recchia F, Kass DA. Systolic flow augmentation in hearts ejecting into a model of stiff aging vasculature. Influence on myocardial perfusiondemand balance. Circ Res. 1995;76 (1):132–141.
  37. Kass DA, Saeki A, Tunin RS, Recchia FA. Adverse influence of systemic vascular stiffening on cardiac dysfunction and adaptation to acute coronary occlusion. Circulation. 1996;93 (8):1533–1541.
  38. Li M, Chiou KR, Bugayenko A et al. Reduced wall compliance suppresses Akt-dependent apoptosis protection stimulated by pulse perfusion. Circ Res. 2005 Sep 16;97 (6):587–95.
  39. Borlaug BA, Melenovsky V, Russell SD et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation. 2006;114 (20):2138–2147.
  40. Warner JG, Metzger DC, Kitzman DW et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol. 1999;33 (6):1567–1572.
  41. Little WC, Zile MR, Klein A et al. Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic dysfunction. Am J Cardiol. 2006;98 (3):383–385.
  42. Hundley WG, Kitzman DW, Morgan TM et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol. 2001;38 (3):796–802.
  43. Jaber W, Nishimura R, Borlaug B et al. Determination of the mecha­nism of elevated left ventricular filling pressures with exercise: A simultaneous echocardiographic-catheterization study. Circulation 2007:1756. (abs)
  44. Bonow RO, Dilsizian V, Rosing DR et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation. 1985;72 (4):853–864.
  45. Setaro JF, Zaret BL, Schulman DS et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol. 1990 Oct 15;66 (12):981–6.
  46. Chen CH, Nakayama M, Talbot M. Verapamil acutely reduces ventricular-vascular stiffening and improves aerobic exercise performance in elderly individuals. J Am Coll Cardiol. 1999;33 (6):1602–9.
  47. Nussbacher A, Gerstenblith G, O'Connor FC et al. Hemodynamic effects of unloading the old heart. Am J Physiol. 1999 Nov;277 (5 Pt 2):H1863–71.
  48. Fleg JL, Schulman S, O'Connor F et al. Effects of acute beta-adre­nergic receptor blockade on age-associated changes in cardiovascular performance during dynamic exercise. Circulation. 1994;90 (5):2333–2341.
  49. Brubaker PH, Joo KC, Stewart KP et al. Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. J Cardiopulm Rehabil. 2006 Mar-Apr;26 (2):86–9.
  50. Kass DA. Ventricular arterial stiffening. Integrating the pathophysiology. Hypertension. 2005;46 (1):185–193
  51. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left – ventricular ejection fraction: the CHARM Preserved Trial. Lancet. 2003;362 (9386):777–781.
  52. Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27 (19):2338–2345.
  53. Pitt B1, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone / enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003 Oct 14;108 (15):1831–8.
  54. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709–717.
  55. Kuwahara F, Kai H, Tokuda K et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106 (1):130–135.
  56. Matsumoto T1, Wada A, Tsutamoto T et al. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003 May 27;107 (20):2555–8.
  57. Tanaka H1, Dinenno FA, Monahan KD et al. Aging, habitual exercise, and dynamic arterial compliance. Circulation. 2000 Sep 12;102 (11):1270–5.
  58. Lai A1, Frishman WH. Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol Rev. 2005 Nov-Dec;13 (6):285–92.
  59. Higashi M1, Shimokawa H, Hattori T et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD (P) H oxidase system. Circ Res. 2003 Oct 17;93 (8):767–75.
  60. Fukuta H, Sane DC, Brucks S et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005;112 (3):357–363.
  61. Morikawa-Futamatsu K, Adachi S, Maejima Y et al. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sci. 2006,29;79 (14):1380–1390.
  62. Kureishi Y, Luo Z, Shiojima I et al. «The HMG-CoA reductase inhibitor simvastatin activates the protein kinase àñt and promotes angiogenesis in normocholesterolemic animals». Nat Med. 2000;6 (9):1004–1010.
  63. Mital S, Zhang X, Zhao G et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol. 2000 Dec;279 (6):H2649–57.
  64. Ferrier KE, Muhlmann MH, Baguet JP et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39 (6):1020–1025.
  65. Shan X, Quaile MP, Monk JK et al. Differential expression of PDE5 in failing and nonfailing human myocardium. Circ Heart Fail. 2012 Jan;5 (1):79–86.
  66. Takimoto E, Champion H. C, Li M. et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11 (2):214–222.
  67. Lewis GD1, Shah R, Shahzad K et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007 Oct 2;116 (14):1555–62.
  68. Melenovsky V1, Al-Hiti H, Kazdova L et al. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. J Am Coll Cardiol. 2009 Aug 11;54 (7):595–600.
  69. Oliver JJ1, Melville VP, Webb DJ. Effect of regular phosphodieste­rase type 5 inhibition in hypertension. Hypertension. 2006 Oct;48 (4):622–7.
  70. Mahmud A, Hennessy M, Feely J. Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens. 2001 Oct;15 (10):707–13.
  71. Katz SD, Balidemaj K, Homma S et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000 Sep;36 (3):845–51.
  72. Borlaug BA1, Melenovsky V, Marhin T et al. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation. 2005 Oct 25;112 (17):2642–9.
  73. Zieman SJ1, Kass DA. Advanced glycation endproduct crosslin­king in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs. 2004;64 (5):459–70.
  74. Yan SF1, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res. 2003 Dec 12;93 (12):1159–69.
  75. Kass DA, Shapiro EP, Kawaguchi M et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104 (13):1464–1470.
  76. Vaitkevicius PV, Lane M, Spurgeon H et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A. 2001 Jan 30;98 (3):1171–5.
  77. Asif M, Egan J, Vasan S et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A. 2000;97 (6):2809–2813.
  78. Fujimoto N1, Hastings JL, Carrick-Ranson G et al. Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals. Circ Heart Fail. 2013 Nov;6 (6):1155–64.
Ovchinnikov A.G., Vitsenya M.V., Kulev B.D. et al. Cardiovascular coupling in heart failure patients with preserved left ventricular ejection fraction. Russian Heart Failure Journal. 2014;84 (3):189–201

To access this material please log in or register

Register Authorize
Ru En